Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Gemcitabine and Carboplatin in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) is a phase 3 interventional study registered as NCT06841354 by Merck Sharp & Dohme LLC, with 1000 participants planned, started 2025-03-16 and due to reach its primary completion in 2030-05-18. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel and Gemcitabine.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Gemcitabine, Pembrolizumab and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Merck & Co. (MSD), Gemcitabine, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.